Noble cold-adapted attenuated mers-cov
AssigneePioneervaccine Inc.
InventorsHeejeong SEO, Yunyueng JANG
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel cold-adapted attenuated Middle East respiratory syndrome coronavirus (MERS-CoV) and uses thereof. According to the present invention, the novel attenuated Middle East respiratory syndrome coronavirus (MERS-CoV) capable of effectively preventing infection with MERS-CoV has been developed by cold-adapting the MERS-CoV gradually, and thus can be effectively used as vaccines and therapeutic agents capable of preventing and treating Middle East respiratory syndrome.
Claims21
A cold-adapted attenuated Middle East respiratory syndrome coronavirus (MERS-CoV) comprising a gene encoding an amino acid in which at least amino acid selected from the group consisting of amino acids at positions 79, 1616, 2088, 2210, 3295, 3735, 3822, 4195, and 4247 in ORF1a polyprotein;
- positions 38, 66, 305, 872, 879, and 1251 in S protein;
- and position 5 in M protein of wild type MERS-CoV is substituted with a sequence different from a wild-type amino acid.
A method for preparing cold-adapted attenuated Middle East respiratory syndrome coronavirus (MERS-CoV) comprising:
- a) infecting cells with MERS-CoV and then adapting the cells gradually from 37° C. to 22° C.;
- and
- b) subculturing the adapted MERS-CoV at 22° C. and then collecting the subcultured MERS-CoV.
-22. (canceled)
Dependencies are inferred from the claim text.